Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk Go et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ+AZ beneficial for COVID-19? Retrospective study in the USA (March - June 2020) Lower mortality with HCQ+AZ (p=0.027) Go et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.935370 Favors HCQ Favors control
Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia
Go et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.935370
Go et al., Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia, Frontiers in Pharmacology, doi:10.3389/fphar.2022.935370
Sep 2022   Source   PDF  
  All Studies   Meta
Retrospective 759 hospitalized patients in the USA, showing lower mortality with combined HCQ+AZ+methylprednisolone treatment compared to methylprednisolone monotherapy.
risk of death, 55.0% lower, HR 0.45, p = 0.03, adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Go et al., 27 Sep 2022, retrospective, USA, peer-reviewed, 2 authors, study period March 2020 - June 2020, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: TYPE Original Research PUBLISHED 27 September 2022 DOI 10.3389/fphar.2022.935370 OPEN ACCESS EDITED BY Sudarshan Singh Rathore, Central Institute of Mining and Fuel Research, India REVIEWED BY Vitaliano Nicola Quaranta, University of Bari Aldo Moro, Italy Venkataraghavan Ramamoorthy, Baptist Health South Florida, United States Asim Bikas Das, National Institute of Technology Warangal, India *CORRESPONDENCE Ronaldo C. Go, SPECIALTY SECTION This article was submitted to Respiratory Pharmacology, a section of the journal Frontiers in Pharmacology RECEIVED 09 May 2022 ACCEPTED 07 September 2022 PUBLISHED 27 September 2022 CITATION Go RC and Nyirenda T (2022), Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID19 pneumonia. Front. Pharmacol. 13:935370. doi: 10.3389/fphar.2022.935370 COPYRIGHT © 2022 Go and Nyirenda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia Ronaldo C. Go 1,2,3* and Themba Nyirenda 1,2 1 Hackensack Meridian School of Medicine, Nutley, NJ, United States, 2Hackensack University Medical Center, Hackensack, NJ, United States, 3Department of Critical Care, Robert Wood Johnson Barnabas Health, Hamilton, NJ, United States Introduction: Severe COVID-19 pneumonia has two phases that are not mutually exclusive. Repurposed drugs target only one phase and the association of combination therapy to survival is unknown. Objective: To determine the association of hydroxychloroquine, azithromycin, and methylprednisolone versus methylprednisolone only to in hospital survival. Methods: This is a secondary analysis of a retrospective cohort of patients admitted for severe covid-19 in 13 hospitals in New Jersey, United States from March–June 2020. Propensity score match with 11 variables was constructed between those who received no methylprednisolone and methylprednisolone. Multivariate Cox regression was used for risk of in hospital mortality. Measurements and main results: There were 759 patients, 380 in no methylprednisolone and 379 with methylprednisolone. Multivariate Cox regression shows that methylprednisolone, hydroxychloroquine, and azithromycin had prolonged survival compared to methylprednisolone alone [HR 0.45 (95% CI 0.22,0.91 p < 0.03)]. In patients who received hydroxychloroquine and azithromycin, those who also received high dose methylprednisolone were associated with worse survival compared to those who received low dose methylprednisolone (HR = 1.642; 95% CI 1.053 to 2.562; p = 0.0287). Nursing home residents [HR 2.77 (95% CI 1.67, 4.59 p < 0.0001)], coronary artery disease [HR 2.93 (95% CI 1.31, 3.15 p = 0.001), and invasive mechanical ventilation [HR 3.02 (95% CI 1.71,5.34 p = 0.0001)] were independently associated with worse survival. Abbreviations: ABG, arterial blood gas; ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; BMI, body mass index; BPM, breaths per minute; CAD, coronary artery disease; CBC,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop